SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending amid an earnings call reporting a substantial operating loss from Bitcoin impairments, fueling a sharp divide as some view it as a buying opportunity for leveraged BTC exposure while others warn of a failing 'ponzi scheme' given the asset's volatility.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

Iris Energy (IREN) is trending amidst a massive sell-off following its earnings report, which revealed a significant miss on revenue and EPS and lower-than-expected AI Cloud services revenue. While some in the community decry the results as a "scam" given the drastic price drop, others point to the company's reaffirmed long-term AI infrastructure targets, secured financing, and strategic shift away from Bitcoin mining as reasons for optimism despite broader sector pressure.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending amid a sharp price decline and mass liquidations, with community discussion heavily influenced by recently surfacing Epstein files, leading to widespread debate over its underlying value and whether current levels signal a generational buying opportunity or further collapse.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending following its recent financial results, as robust growth in AWS and overall revenue are overshadowed by a substantial future capital expenditure forecast for AI and other innovative technologies. This aggressive investment plan is generating significant market debate, with investors divided between concerns over immediate returns and viewing the pullback as a long-term buying opportunity.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is experiencing a sharp market downturn, reflecting broader cryptocurrency weakness, as the community debates whether institutional manipulation or fundamental shifts are driving the extensive sell-off. While many express panic over significant portfolio losses, a strong contingent views current levels as a prime accumulation phase for long-term potential, eagerly awaiting further dips to buy the fear.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPDR S&P 500 ETF Trust is trending significantly lower, driven by a broad tech sector rout that intensified after major companies like Amazon experienced post-earnings drops. The community is expressing overwhelmingly bearish sentiment, questioning the immediate profitability of massive AI capital expenditures and discussing a widespread "risk-off" shift across equities and crypto markets.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is a major talking point as the tech sector experiences a broad sell-off, fueled by investor concerns over mega-cap AI capital expenditure, notably from Amazon, and a wider market reevaluation of growth versus profitability, which the community is actively debating as a potential market reset.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is at the center of investor conversation following a sharp decline, sparking intense debate over whether the sell-off is an unwarranted market overreaction or manipulation, especially given major hyperscalers' recently announced massive capital expenditures for AI infrastructure, with all eyes now on upcoming earnings.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull (BULL) is trending due to a significant and sustained price decline, with community members attributing the drop to broader market corrections and a strong, albeit questioned, correlation with recent cryptocurrency pullbacks. Intense discussion highlights investor frustration, speculation about market manipulation, and a sharp divide between those advocating to "buy the dip" and others warning of a "falling knife" amidst calls for management to address the ongoing downturn.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining (CIFR) is heavily discussed as it navigates sector volatility, with a recent $2 billion senior secured notes offering for its Amazon-leased Black Pearl data center fueling its strategic expansion into AI infrastructure. While the community debates market manipulation and Bitcoin's impact, investors emphasize CIFR's significant hyperscaler contracts and low-cost power as core strengths for its pivot to high-performance computing.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Given Average Recommendation of "Moderate Buy" by Brokerages

Tectonic Therapeutic, Inc. (NASDAQ:TECX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seven analysts that are covering the firm, MarketBeat.com reports. One...

Tectonic Therapeutic (NASDAQ:TECX) Trading Down 0.8% - Time to Sell?

Tectonic Therapeutic (NASDAQ:TECX) Trading Down 0.8% - What's Next...

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Tectonic Therapeutic, Inc. (NASDAQ:TECX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the stock...

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Tectonic Therapeutic, Inc. (NASDAQ:TECX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the firm, MarketBeat.com reports...

Tectonic Therapeutic (NASDAQ:TECX) Issues Earnings Results, Beats Estimates By $0.03 EPS

Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($1.02) EPS for the quarter, beating analysts' consensus estimates of...

<ul class="summary-bullets"><li>TX45, Tectonic’s experimental Fc-relaxin fusion protein, showed strong improvements in heart and lung function with no serious safety issues in patients with heart failure-related pulmonary hypertension.</li><li>The results expand the drug’s potential reach to a broader patient population with no approved therapies, while the Phase 2 APEX trial continues toward results in 2026.</li><li>Retail investors reacted enthusiastically on Stocktwits, calling the data “unbelievable” and “outstanding.”&nbsp;</li></ul>Shares of Tectonic Therapeutic rose about 30% in after-hours trading on Wednesday after the company reported positive topline results from a Phase 1b Part B clinical trial of TX45, its experimental Fc-relaxin fusion protein, in patients with Group 2 pulmonary hypertension associated with heart failure with reduced ejection fraction.<h2 class="st-heading-2">TX45 Shows Improvements In Heart And Lung Function</h2>Tectonic said a single intravenous dose of TX45 was well tolerated, with no serious side effects or meaningful changes in blood pressure. The treatment showed clear benefits for heart and lung function by reducing pressure on the heart and lungs and improving blood flow. Key measures, such as pulmonary capillary wedge pressure, total pulmonary resistance, and mean pulmonary artery pressure, all decreased, while cardiac output increased.CEO Alise Reicin said the findings “open up the potential to expand into this additional patient population with significant unmet need and no approved therapies,” adding that the results mirrored those seen in an earlier TX45 study in heart failure with preserved ejection fraction.<h2 class="st-heading-2">Broader Development Plan</h2>The trial enrolled 14 patients and builds on earlier positive data from TX45’s Phase 1b Part A study in ejection fraction. The company is currently running the APEX Phase 2 trial to test TX45 over a 24-week treatment period in patients with ejection fraction, with topline results expected in 2026.Chief Medical Officer Marcella Ruddy said the drug showed “persistent effects at day 29” based on echocardiographic data and continued to demonstrate a favorable safety profile.<h2 class="st-heading-2">Stocktwits Users Cheer Tectonic’s TX45 Results</h2>On Stocktwits, retail sentiment for Tectonic Therapeutic was ‘extremely bullish’ amid ‘extremely high’ message volume.One user described the TX45 results as “unbelievable,” predicting the stock could reach $50.&nbsp;<stembedurl>https://stocktwits.com/paddypablo/message/634229088</stembedurl>Another user said the data looked “outstanding,” adding to their position below $22 and expecting the shares to climb further.<stembedurl>https://stocktwits.com/Gurujoe/message/634224719</stembedurl><a href="https://stocktwits.com/symbol/TECX">Tectonic’s stock</a> has declined 60% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tectonic’s stock (TECX) has declined 60% so far in 2025. (Photo credit: Getty Images)

Why Tectonic Therapeutic Stock Soared 30% After-Hours Today

TX45, Tectonic’s experimental Fc-relaxin fusion protein, showed strong improvements in heart and lung function with no serious safety issues in patients with heart failure-related pulmonary hypertension.

Equity

Shares of Tectonic Therapeutic (TECX) soared about 6% in Wednesday’s pre-market after Oppenheimer initiated coverage of the company with an ‘Outperform’ rating.Oppenheimer has an $80 price target on Tectonic, representing an upside of over 380% from the stock’s closing price on Tuesday. The firm stated that it likes the prospects of Tectonic's lead asset, TX45, for addressing prevalent and progressive cardiovascular disorders that are currently inadequately treated.The analyst is optimistic ahead of next year's mid-stage study data readout in pulmonary hypertension with heart failure with preserved ejection fraction, which it believes could pave the way for a multi-billion-dollar global sales opportunity, according to TheFly.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TECX">Tectonic</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_03_at_7_02_32_AM_png_aa449b866b.webp" alt="TECX's Sentiment Meter and Message Volume as of 7:02 a.m. ET on Sept. 3, 2025 | Source: Stocktwits" width="577" height="62"><figcaption>TECX's Sentiment Meter and Message Volume as of 7:02 a.m. ET on Sept. 3, 2025 | Source: Stocktwits</figcaption></figure>Tectonic shares closed down 35% on Tuesday following Eli Lilly's (LLY) data presentation and publication from its failed study in heart failure patients with preserved ejection fraction using a recombinant long-acting relaxin mimetic, Volenrelaxin. Tectonic’s lead candidate also seeks to treat similar cardiovascular disorders.According to Truist analyst Danielle Brill, the negative news "represents another hit to the emerging relaxin class of drugs." Still, the firm also notes that read-through should be limited as the population enrolled in Lilly's trial is distinct from those enrolled in Tectonic's.The firm, which believes Tectonic's approach to targeting Combined Post- and Pre-Capillary Pulmonary Hypertension has "the strongest rationale" and calls the selloff "overdone," maintained a ‘Buy’ rating and a $64 price target on Tectonic shares.TECX stock is down by 64% this year and by about 13% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/cybersecurity-vendor-zscaler-s-stock-rises-premarket-what-s-fueling-upside/chwTMR0Rd89">Cybersecurity Vendor Zscaler’s Stock Rises Premarket: What’s Fueling The Upside?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Tectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead Candidate

Oppenheimer stated that it likes the prospects of Tectonic's lead asset, TX45, to address prevalent and progressive cardiovascular disorders that are inadequately treated.

Raymond James bullish on biotech firms on favorable valuation

Investing.com -- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and Wave Life Sciences (NASDAQ:WVE), pointing to a sector-wide opportunity amid “suppressed valuations.”

Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High?

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). It develops a proprietary technology platform called GEODe to enable the discovery and development of GPCR-targeted biologic medicines. The company was founded by Timothy A. Springer and Andrew Kruse in November 2015 and is headquartered in Watertown, MA.

TECX
Tectonic Therapeutic Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TECX News

TECXTectonic Therapeutic Inc.